Insider · CIK 0001434718
James F Oliviero III
Files at CKPT (Checkpoint Therapeutics, Inc.), NVCT (Nuvectis Pharma, Inc.). First filing Dec 20, 2024, latest Apr 3, 2025.
In brief
James F Oliviero III files SEC Form 4 as CEO, president and director at CKPT (Checkpoint Therapeutics, Inc.), and also at NVCT (Nuvectis Pharma, Inc.). Since Dec 20, 2024, James F Oliviero III has reported 0 open-market buys worth $0 and 3 open-market sells worth $3.2M, the latest filed on Apr 3, 2025.
A track record needs three past buys with six months of prices behind them; James F Oliviero III has 0, so none is measured yet.
The newest scored trade: sold $61k of CKPT on Apr 2, 2025, filed Apr 3, 2025, scored 40 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Checkpoint Therapeutics, Inc. | $61k 15,090 shares | -0% | - | |
| 41Moderate | Checkpoint Therapeutics, Inc. | $64k 19,564 shares | -1% | - | |
| 63Notable | Checkpoint Therapeutics, Inc. | $3.1M 822,397 shares | -20% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | NVCT Nuvectis Pharma, Inc. | AGrant or award Common Stock | +35,000 | $0.00 | $0 | 122,828 | Jun 12, 2026 |
| Jun 12, 2025 | NVCT Nuvectis Pharma, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 87,828 | Jun 12, 2025 |
| May 30, 2025 | CKPT Checkpoint Therapeutics, Inc. | UTender of shares COMMON STOCK | -3,759,929 | - | - | 0 | May 30, 2025 |
| Apr 2, 2025 | CKPT Checkpoint Therapeutics, Inc. | SOpen-market sale COMMON STOCK | -15,090 | $4.04 | $61k | 3,759,929 | Apr 3, 2025 |
| Feb 7, 2025 | CKPT Checkpoint Therapeutics, Inc. | SOpen-market sale COMMON STOCK | -9,233 | $3.41 | $31k | 3,785,350 | Feb 11, 2025 |
| Feb 10, 2025 | CKPT Checkpoint Therapeutics, Inc. | SOpen-market sale COMMON STOCK | -10,331 | $3.15 | $33k | 3,775,019 | Feb 11, 2025 |
| Jan 30, 2025 | CKPT Checkpoint Therapeutics, Inc. | AGrant or award COMMON STOCK (RESTRICTED) | +1,500,000 | $0.00 | $0 | 3,794,583 | Jan 31, 2025 |
| Dec 18, 2024 | CKPT Checkpoint Therapeutics, Inc. | SOpen-market sale COMMON STOCK | -602,167 | $3.87 | $2.3M | 3,414,813 | Dec 20, 2024 |
| Dec 19, 2024 | CKPT Checkpoint Therapeutics, Inc. | SOpen-market sale COMMON STOCK | -220,230 | $3.38 | $744k | 3,194,583 | Dec 20, 2024 |
| Dec 20, 2024 | CKPT Checkpoint Therapeutics, Inc. | GGift COMMON STOCK | -900,000 | $0.00 | $0 | 2,294,583 | Dec 20, 2024 |
| Dec 13, 2024 | CKPT Checkpoint Therapeutics, Inc. | AGrant or award COMMON STOCK | +2,077,700 | $0.00 | $0 | 4,016,980 | Dec 17, 2024 |
Questions about James F Oliviero III
Answered from the filings on this page, as of the latest one.
Is James F Oliviero III buying or selling?
Not in the last 12 months. James F Oliviero III's latest open-market trade on SEC Form 4 was sold $61k of CKPT on Apr 2, 2025.
How did James F Oliviero III's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James F Oliviero III has 0.
Where does James F Oliviero III file Form 4?
James F Oliviero III has filed Form 4 at CKPT (Checkpoint Therapeutics, Inc.) as CEO, President and Director; NVCT (Nuvectis Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.